

July 28, 2026

The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor
Plot No. C1, 'G' Block, Bandra-Kurla Complex
Bandra (East), Mumbai 400 051.

BSE Limited
Corporate Relationship Department
Floor
25, P.J. Towers
Dalal Street
Mumbai 400 001.

Symbol: RPGLIFE

Scrip code: 532983

Dear Sir/Madam,

Sub: Outcome of Board Meeting of the Company held on July 28, 2026.

In terms of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company at its meeting held on Tuesday, July 28, 2026, inter-alia considered and unanimously approved, the unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter ended June 30, 2026, together with Limited Review Reports issued by the Statutory Auditors of the Company are enclosed herewith in terms of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The meeting commenced at 03:00 p.m. and concluded at 6.30 p.m.

Kindly take the same on record.

Thanking you,

Yours faithfully,
For RPG Life Sciences Limited

Rajesh Shirambekar
Head – Legal & Company Secretary
Encl.- as above

Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**Review Report to
The Board of Directors
RPG Life Sciences Limited**

1. We have reviewed the accompanying statement of unaudited standalone financial results of RPG Life Sciences Limited (the "Company") for the quarter ended June 30, 2026 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. The Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For S R B C & COLLP

Chartered Accountants

ICAI Firm registration number: 324982E/E300003**per Aruna Kumaraswamy**

Partner

Membership No.: 219350

UDIN: 26219350EYCFED6139

Place: Mumbai

Date: July 28, 2026



STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2026

Particulars	(Rs. in Lakhs)			
	Quarter ended			Year ended
	30-06-2026	31-03-2026	30-06-2025	31-03-2026
	Unaudited	Audited	Unaudited	Audited
1 Revenue from Operations	19,569	17,689	16,892	70,752
2 Other Income (Refer note 3(a))	416	1,236	523	2,554
3 Total Income (1+2)	19,985	18,925	17,415	73,306
4 Expenses				
(a) Cost of Materials Consumed	3,768	3,643	3,204	13,598
(b) Purchases of Stock-in-Trade	3,953	2,263	3,306	13,810
(c) Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	(906)	153	(508)	(2,199)
(d) Employee Benefits Expense	3,776	3,630	3,370	14,148
(e) Finance Costs	63	39	13	89
(f) Depreciation and Amortisation Expense	590	574	514	2,148
(g) Other Expenses	4,620	4,713	3,973	16,682
Total Expenses	15,864	15,015	13,872	58,276
5 Profit before exceptional items and tax (3-4)	4,121	3,910	3,543	15,030
6 Exceptional items (net) (Refer Note 3)	-	110	-	390
7 Profit before tax	4,121	4,020	3,543	15,420
8 Income tax expenses				
a. Current Tax	1,076	721	907	3,475
b. Deferred Tax	(12)	309	7	428
Total tax expenses	1,064	1,030	914	3,903
9 Profit for the period (7-8)	3,057	2,990	2,629	11,517
10 Other Comprehensive Income				
(i) Items that will not be reclassified to Profit or Loss	(20)	10	(2)	(86)
(ii) Income tax relating to items that will not be reclassified to Profit or Loss	5	(2)	1	22
Other Comprehensive Income / (Loss) Net of Tax	(15)	8	(1)	(64)
11 Total Comprehensive Income for the period (9+10)	3,042	2,998	2,628	11,453
12 Paid-up Equity Share Capital (Face Value Rs. 8/- each)	1,323	1,323	1,323	1,323
13 Other Equity				59,214
14 Earnings per Share (of Rs. 8/- each) (not annualised for the quarter):				
(a) Basic (in Rs.)	18.49	18.08	15.90	69.64
(b) Diluted (in Rs.)	18.49	18.08	15.90	69.64

SIGNED FOR IDENTIFICATION
BY

S R B C & CO LLP
MUMBAI



Notes:

- The above unaudited standalone financial results of the Company have been reviewed and recommended by the Audit Committee and have been approved by the Board of Directors at their respective meeting held on July 28, 2026.
- The Company operates in only one reportable business segment i.e. Pharmaceuticals.
- Exceptional items:


Exceptional Income / (Expenses)	(Rs. in Lakhs)			
	Quarter ended		Year ended	
	30-06-2026	31-03-2026	30-06-2025	31-03-2026
	Unaudited	Audited	Unaudited	Audited
Net impact of Insurance claim on loss arising on account of fire incident - Refer note 3(a)	-	1,087	-	2,475
Impact of New Labour Codes - Refer note 3(b)	-	(61)	-	(1,169)
Impairment of Intangible Assets Under Development (IAUD) - Refer note 3(c)	-	(916)	-	(916)
Total exceptional items - Income	-	110	-	390

- During the year ended March 31, 2026, the Company received full settlement of the insurance claim relating to the fire incident at its Navi Mumbai API plant which occurred in January 2025. The settlement resulted in a net income of Rs. 2,475 lakhs which was recognized as Exceptional income in the respective quarters during FY26 when such claim proceeds were received. The Company had also recognized Rs. 791 lakhs received towards compensation for business interruption losses as Other income during the quarter ended March 31, 2026.
 - During the year ended March 31, 2026, the Company recognised an exceptional expense of Rs. 1,169 lakhs towards the impact of the New Labour Codes notified effective November 22, 2025, primarily arising from the change in wage definition. The Company continues to monitor further regulatory developments and will account for any additional impact, if required.
 - Exceptional items for the quarter and year ended March 31, 2026 includes write-off of an intangible asset under development. Based on management's annual assessment of impairment, no future economic benefits were expected to arise from the project. Accordingly, the accumulated costs incurred up to that date were written off and recognised as an exceptional item.
- The Board of Directors of the Company, at its meeting held on December 15, 2025, approved the transfer of the API division ("the Division") of the Company, to its wholly owned subsidiary (WOS) viz. RPG Active Pharma Limited, which was incorporated on December 24, 2025, subject to receipt of all requisite consents. The Company expects the transaction to be concluded upon receipt of the requisite approvals and completion of customary conditions precedent.
- Figures of the quarter ended March 31, 2026 are the balancing figure between audited figures in respect of the full financial year and unaudited published year to date figure up to December 31, 2025 which were subjected to limited review by Auditors.


Place: Mumbai
Date: July 28, 2026



For RPG Life Sciences Limited



Ashok Nair
Managing Director
DIN: 07906710



Independent Auditor's Review Report on the Quarterly Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

**Review Report to
The Board of Directors
RPG Life Sciences Limited**


1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of RPG Life Sciences Limited (the "Holding Company") and its subsidiary (the Holding Company and its subsidiary together referred to as "the Group") for the quarter ended June 30, 2026 (the "Statement") attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. The Holding Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Holding Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Master Circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.
4. The Statement includes the results of the subsidiary Company 'RPG Active Pharma Limited'.
5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For S R B C & CO LLP

Chartered Accountants

ICAI Firm registration number: 324982B/E300003



per Aruna Kumaraswamy
Partner

Membership No.: 219350

UDIN: 26219350WTPJEV 3772

Place: Mumbai

Date: July 28, 2026



STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2026

Particulars	(Rs. in Lakhs)			
	Quarter ended		Year ended	
	30-06-2026	31-03-2026	30-06-2025	31-03-2026
	Unaudited	Audited	Unaudited	Audited
1 Revenue from Operations	19,569	17,689	16,892	70,752
2 Other Income (Refer note 3(a))	470	1,240	523	2,558
3 Total Income (1+2)	20,039	18,929	17,415	73,310
4 Expenses				
(a) Cost of Materials Consumed	3,768	3,643	3,204	13,598
(b) Purchases of Stock-in-Trade	3,953	2,263	3,306	13,810
(c) Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	(906)	153	(508)	(2,199)
(d) Employee Benefits Expense	3,776	3,630	3,370	14,148
(e) Finance Costs	63	39	13	89
(f) Depreciation and Amortisation Expense	590	574	514	2,148
(g) Other Expenses	4,649	4,717	3,973	16,686
Total Expenses	15,893	15,019	13,872	58,280
5 Profit before exceptional items and tax (3-4)	4,146	3,910	3,543	15,030
6 Exceptional items (net) (Refer Note 3)	-	110	-	390
7 Profit before tax	4,146	4,020	3,543	15,420
8 Income tax expenses				
a. Current Tax	1,082	721	907	3,475
b. Deferred Tax	(12)	309	7	428
Total tax expenses	1,070	1,030	914	3,903
9 Profit for the period (7-8)	3,076	2,990	2,629	11,517
10 Other Comprehensive Income				
(i) Items that will not be reclassified to Profit or Loss	(20)	10	(2)	(86)
(ii) Income tax relating to items that will not be reclassified to Profit or Loss	5	(2)	1	22
Other Comprehensive Income / (Loss) Net of Tax	(15)	8	(1)	(64)
11 Total Comprehensive Income for the period (9+10)	3,061	2,998	2,628	11,453
12 Paid-up Equity Share Capital (Face Value Rs. 8/- each)	1,323	1,323	1,323	1,323
13 Other Equity				59,212
14 Earnings per Share (of Rs. 8/- each) (not annualised for the quarter):				
(a) Basic (in Rs.)	18.60	18.08	15.90	69.64
(b) Diluted (in Rs.)	18.60	18.08	15.90	69.64

SIGNED FOR IDENTIFICATION
BY *AK*
S R B C & CO LLP
MUMBAI



Notes:

1. The above unaudited consolidated financial results of the Group have been reviewed and recommended by the Audit Committee and have been approved by the Board of Directors at their respective meeting held on July 28, 2026.

2. The Group operates in only one reportable business segment i.e. Pharmaceuticals.

3. Exceptional items:

Exceptional Income / (Expenses)	(Rs. in Lakhs)			
	Quarter ended		Year ended	
	30-06-2026	31-03-2026	30-06-2025	31-03-2026
	Unaudited	Audited	Unaudited	Audited
Net impact of Insurance claim on loss arising on account of fire incident - Refer note 3(a)	-	1,087	-	2,475
Impact of New Labour Codes - Refer note 3(b)	-	(61)	-	(1,169)
Impairment of Intangible Assets Under Development (IAUD) - Refer note 3(c)	-	(916)	-	(916)
Total exceptional items - Income	-	110	-	390

3(a) During the year ended March 31, 2026, the Group received full settlement of the insurance claim relating to the fire incident at its Navi Mumbai API plant which occurred in January 2025. The settlement resulted in a net income of Rs. 2,475 lakhs which was recognized as Exceptional income in the respective quarters during FY26 when such claim proceeds were received. The Group had also recognized Rs. 791 lakhs received towards compensation for business interruption losses as Other income during the quarter ended March 31, 2026.

3(b) During the year ended March 31, 2026, the Group recognised an exceptional expense of Rs. 1,169 lakhs towards the impact of the New Labour Codes notified effective November 22, 2025, primarily arising from the change in wage definition. The Group continues to monitor further regulatory developments and will account for any additional impact, if required.

3(c) Exceptional items for the quarter and year ended March 31, 2026 includes write-off of an intangible asset under development. Based on management's annual assessment of impairment, no future economic benefits were expected to arise from the project. Accordingly, the accumulated costs incurred up to that date were written off and recognised as an exceptional item.


4. The Board of Directors of the Company, at its meeting held on December 15, 2025, approved the transfer of the API division ("the Division") of the Company, to its wholly owned subsidiary (WOS) viz. RPG Active Pharma Limited, which was incorporated on December 24, 2025, subject to receipt of all requisite consents. The Group expects the transaction to be concluded upon receipt of the requisite approvals and completion of customary conditions precedent.

5. Figures of the quarter ended March 31, 2026 are the balancing figure between audited figures in respect of the full financial year and unaudited published year to date figure up to December 31, 2025 which were subjected to limited review by Auditors.

Place: Mumbai
Date: July 28, 2026



For RPG Life Sciences Limited


Ashok Nair
Managing Director
DIN: 07906710

